EXHIBIT CC

. Case 2:08-cv-03573-MR_JEM Document 291-9 Filed 07/27/10 Page 2015 Page ID #:7079

All communications respecting this case should identify it by number and names of parties.



U.S. DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: BOX INTERFERENCE

Commissioner of Patents and Trademarks Washington, D.C. 20231

Telephone: (703)557-4007 Facsimile: (703)557-8642

್ಷ್ ಪ್ರ∗್ಯಾಕ್ .ು

MAILED

FFB 2 8 1991

JOARD OF PATENT APPEALS AND INTERFERENCES

Applicants: Cabilly et al Serial No.: 07/205,419 Filed: June 10, 1988

For: RECOMBINANT IMMUNOGLOBIN

PREPARATIONS

Accorded Benefit of: U.S. S.N. 06/483,457, filed 04/08/83, now Patent No. 4,816,567, issued 03/28/89

The case referred to above has been forwarded to the Board of Patent Appeals and Interferences because it is adjudged to interfere with other cases hereafter specified. Attention is directed to the fact that this interference is declared pursuant to 37 CFR 1.601 et seq., effective February 11, 1985 (49 F.R. 48416. 1050 O.G. 385). The interference is designated as No. 102,572.

By direction of the Commissioner of Patents and Trademarks and as required by 35 USC 135(c), notice is hereby given the parties of the requirement of the law for filing in the Patent and Trademark Office a copy of any agreement "in connection with or in contemplation of the termination of the interference."

Serial No. 205,419

-2-

The cases involved in this interference are:

Junior Party

Patentees: Michael A. Boss, John H. Kenten, John S. Emtage and Clive R. Wood

Address: 20 Hunter Court, Huntercombe Lane North, Slough,
Berkshire, SL1 6DS, U.K.
24 Avery Avenue, Downley, High Wycombe, Buckinghamshire,
U.K.
12 Benjamin House, Amersham Hill, High Wycombe,

Buckinghamshire, U.K.

'Whych Wood', Buddle Hill, North Gorley, Near Fordingbridge, Hampshire, U.K.

Serial No.: 06/672,265, filed 11/14/84, now Patent No. 4,816,397, issued 03/28/89

For: MULTICHAIN POLYPEPTIDES OR PROTEINS AND PROCESSES FOR THEIR PRODUCTION

Assignee: Celltech Limited, Berkshire SL1 4DY, U.K., A British Company

Attorneys of Record: Paul N. Kokulis, Allen Kirkpatrick,
Lloyd J. Street, George T. Mobille, James L. Dooley,
Alvin Guttag, Raymond F. Lippitt, G. Lloyd Knight,
Carl G. Love, Lawrence A. Hymo, Akin T. Davis,
Edgar H. Martin, William K. West, Jr., Kevin E.
Joyce, Edward M. Prince, Donald B. Deaver, David W.
Brinkman, George M. Sirilla, William T. Bullinger,
Donald J. Bird, Larry S. Nixon, James R. Longacre,
Arthur R. Crawford, W. Warren Taltavull, Michael L.
Keller, Charles R. Donohoe, Sherman O. Parrett,
Robert A. Vanderhye, Watson T. Scott, Peter W.
Gowdey, Michael A. Lechter, Dale S. Lazar, James T.
Hosmer and Glenn J. Perry

Associate Attorney: None

Accorded Benefit of: None

Address: Cushman, Darby & Cushman

Eleventh Floor 1615 L Street, N.W. Washington, DC 20036 Serial No. 205,419

-3**-**

Senior Party

Applicants: Shmuel Cabilly, Herbert L. Heyneker,

William E. Holmes, Arthur D. Riggs and

Ronald B. Wetzel

Address: 2038 S. Peck, Monrovia, CA 91016

2621 Easton Drive, Burlingame, CA 94010

29 Eastlake, Pacifica, CA 94044

4852 St. Andres Avenue, La Verne, CA 91750 76 Melrose Avenue, San Francisco, CA 94131

Serial No.: 07/205,419, filed 06/10/88

For: RECOMBINANT IMMUNOGLOBULIN PREPARATIONS

Assignee: Genentech, Inc., South San Francisco, CA, A California

Corporation

Attorneys of Record: Walter H. Dreger, Thomas D. Kiley,

Kate H. Murashige, Max D. Hensley and Janet E. Hasak

Associate Attorneys: None

Accorded Benefit of: U.S. S.N. 06/483,457, filed 04/08/83, now

Patent No. 4,816,567, issued 03/28/89

Address: Max D. Hensley

Genentech, Inc.

460 Point San Bruno Blvd. So. San Francisco, CA 94080 Serial No. 205,419

-4-

Count 1

A process for producing an Ig molecule or an immunologically functional Ig fragment comprising at least the variable domains of the Ig heavy and light chains, in a single host cell, comprising the steps of:

- (i) transforming said single host cell with a first DNA sequence encoding at least the variable domain of the Ig heavy chain and a second DNA sequence encoding at least the variable domain of the Ig light chain, and
- (ii) independently expressing said first DNA sequence and said second DNA sequence so that said Ig heavy and light chains are produced as separate molecules in said transformed single host cell.

The claims of the parties which correspond to this

count are:

Boss et al: Claims 1-18.

Cabilly et al: Claims 101-120.

Mary W. Downey Examiner-in-Chief

(703) 557-4003

MFD/raj